GOSS Stock Forecast & Price Target

Gossamer Bio is viewed favorably because seralutinib addresses a large unmet need in PAH with a differentiated inhaled TKI mechanism that is anti-proliferative, anti-inflammatory, and anti-fibrotic rather than another vasodilator. The Phase 3 PROSERA result of p=0.032 on 6MWD, plus supportive TORREY and CT FRI data, strengthens the totality-of-evidence NDA strategy and suggests meaningful benefit across a broad patient population, including CTD-APAH and moderate-to-high-risk patients. Financially, the convertible note exchange is expected to fund operations through potential approval, while the planned September NDA submission and potential 2H27 launch improve visibility on execution and reduce balance-sheet risk.

Gossamer Bio is viewed cautiously because its value is highly dependent on seralutinib, a single clinical asset with only partial probability of success in PAH and PH-ILD, while clinical and commercialization setbacks could materially weaken the investment case. The outlook is further pressured by funding needs and dilution risk, including an expected $200M gross capital raise in 2028E, the $46M warrant exercise in 2027E, and up to $250M from the August 2026 private placement, all of which may increase share count. The negative stance also reflects lower conviction in execution, with delays pushing potential approval to ~3Q27 versus ~2Q27, a reduced PoS to 75% from 95%, and lowered peak seralutinib sales to about $2.3B from about $2.5B.